Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual dexmedetomidine dose comparison for pain relief in mechanically ventilated ICU patients
IRCT20160307026950N82Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of dexmedetomidine in pain (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Pain intensity before administration, Pain intensity one hour after administration and 1 more. Started Jul 2026; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
pain
Beyond the preview
Go deeper on IRCT20160307026950N82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160307026950N82.